Nucleonics goes long in RNAi

RNAi is a hot concept, but hurdles to producing viable clinical candidates include stability, specificity and inflammation. Nucleonics Inc. plans to sidestep many of these hurdles, allowing the company to be in the clinic in about 18 months.

RNA interference uses the introduction of double-stranded RNA (dsRNA) into a cell to inhibit gene expression in a sequence-dependent fashion. ...